TY - JOUR AU - Howell, G. AU - West, L. AU - Jenkins, C. AU - Lineberry, B. AU - Yokum, D. AU - Rockhold, R. PY - 2005 DA - 2005/08/18 TI - In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine JO - BMC Pharmacology SP - 13 VL - 5 IS - 1 AB - Muscarinic receptor mediated adverse effects, such as sedation and xerostomia, significantly hinder the therapeutic usefulness of first generation antihistamines. Therefore, second and third generation antihistamines which effectively antagonize the H1 receptor without significant affinity for muscarinic receptors have been developed. However, both in vitro and in vivo experimentation indicates that the third generation antihistamine, desloratadine, antagonizes muscarinic receptors. To fully examine the in vivo antimuscarinic efficacy of desloratadine, two murine and two rat models were utilized. The murine models sought to determine the efficacy of desloratadine to antagonize muscarinic agonist induced salivation, lacrimation, and tremor. Desloratadine's effect on the cardiovascular system was explored in both rodent models. SN - 1471-2210 UR - https://doi.org/10.1186/1471-2210-5-13 DO - 10.1186/1471-2210-5-13 ID - Howell2005 ER -